Nephrotic Syndrome Management

Initial Diagnostic Workup and Supportive Management

• The initial workup for nephrotic syndrome should include investigations to exclude secondary causes, followed by supportive management with sodium restriction, diuretics, and ACE inhibitors/ARBs, while immunosuppressive therapy should be tailored based on the underlying pathology identified through kidney biopsy, as recommended by the Kidney International guidelines 1, 2
• Confirm nephrotic-range proteinuria with 24-hour urine collection or spot urine protein-to-creatinine ratio, according to Kidney International 1
• Perform investigations to exclude secondary causes in all cases, including diabetes mellitus, systemic lupus erythematosus, infections, and medications review, as suggested by Kidney International and Nature Reviews Nephrology 1, 3, 4
• Restrict dietary sodium to <2.0 g/day to reduce edema and help manage proteinuria, as recommended by Praxis Medical Insights 2
• Use loop diuretics as first-line agents for edema management, according to Praxis Medical Insights 2
• Initiate ACE inhibitors or ARBs at maximally tolerated doses for proteinuria and blood pressure control, as suggested by Praxis Medical Insights 2
• Target systolic blood pressure <120 mmHg in adults using standardized office BP measurement, as recommended by Praxis Medical Insights 2

Kidney Biopsy Indications and Specific Treatment

• In children with typical presentation, biopsy may be deferred if there is response to initial steroid therapy, according to American Journal of Kidney Diseases and Kidney International 5, 6
• Biopsy is indicated in steroid-resistant nephrotic syndrome in children, as suggested by Kidney International 6
• For minimal change disease, oral prednisone/prednisolone at 1 mg/kg/day (max 80 mg) or alternate-day dose of 2 mg/kg (max 120 mg) is recommended, according to Kidney International 6
• For focal segmental glomerulosclerosis, confirm idiopathic FSGS before initiating immunosuppressive therapy, as suggested by Kidney International 4
• For membranous nephropathy, initial therapy should be started only when urinary protein persistently exceeds 4 g/day and remains >50% of baseline despite 6 months of conservative therapy, or severe, disabling symptoms are present, according to Kidney International 1, 7

Monitoring and Complications Management

• Administer pneumococcal and influenza vaccines to prevent infections, as recommended by Praxis Medical Insights 2
• Consider prophylactic trimethoprim-sulfamethoxazole for patients receiving high-dose immunosuppression, according to Praxis Medical Insights 2
• Regularly assess proteinuria and kidney function to evaluate treatment response, as suggested by Praxis Medical Insights 2
• Monitor for side effects of medications, particularly with long-term immunosuppressive therapy, according to Praxis Medical Insights 2

Special Considerations

• Refer children with congenital nephrotic syndrome to specialized pediatric nephrology units, as recommended by Nature Reviews Nephrology 3
• Avoid intravenous fluids and saline; concentrate oral fluid intake if necessary, according to Nature Reviews Nephrology 3
• Use albumin infusions based on clinical indicators of hypovolaemia, not serum albumin levels, as suggested by Nature Reviews Nephrology 3
• Consider ambulatory management when possible to improve quality of life and reduce infection risk, according to Nature Reviews Nephrology 3

Initial Management of Nephrotic Syndrome

Corticosteroid Therapy

• The American College of Cardiology is not mentioned, however, the Kidney International guideline recommends administering prednisone at 1 mg/kg/day (maximum 80 mg) or alternate-day dose of 2 mg/kg (maximum 120 mg) for adults with nephrotic syndrome 8
• The American Journal of Kidney Diseases guideline recommends administering prednisone at 60 mg/m² per day (maximum 80 mg/day) or 2 mg/kg/day for 4-6 weeks for children with nephrotic syndrome 9
• The Kidney International guideline recommends continuing high-dose corticosteroids for a minimum of 4 weeks and up to 16 weeks as tolerated or until complete remission, then tapering corticosteroids slowly over a period of 6 months after achieving complete remission 8

Alternative First-Line Therapy

• The Kidney International guideline recommends considering calcineurin inhibitors (CNIs) as first-line therapy for patients with relative contraindications or intolerance to high-dose corticosteroids, with cyclosporine dosing at 3-5 mg/kg/day divided into 2 doses and tacrolimus dosing at 0.1-0.2 mg/kg/day divided into 2 doses 10

Special Considerations

• The American Journal of Kidney Diseases guideline recommends considering steroid-sparing agents such as cyclophosphamide, levamisole, or calcineurin inhibitors in children with frequently relapsing or steroid-dependent nephrotic syndrome 11

Nephrotic Syndrome Diagnosis and Management

Diagnostic Considerations

• Genetic testing should be considered as a first-line diagnostic measure, especially in congenital or early-onset cases, using massively parallel sequencing or whole-exome sequencing, to identify non-kidney manifestations of hereditary forms, according to the Nature Reviews Nephrology 12
• Extended diagnostic workup should identify non-kidney manifestations of hereditary forms, including neurological status, sight, hearing, and dysmorphic features, as recommended by the Nature Reviews Nephrology 12

Special Patient Populations

• For congenital nephrotic syndrome, referral to specialized pediatric nephrology units is recommended, as stated in the Nature Reviews Nephrology 12
• Early referral to a transplant center should be considered for patients with progressive disease to minimize time on dialysis, according to the Nature Reviews Nephrology 12

Pulse Glucocorticoid Therapy for Acute Severe Nephrotic Syndrome

Initial Pulse Regimen

• In adult or pediatric patients with acute severe nephrotic syndrome, administer three consecutive daily intravenous methylprednisolone pulses of 500–750 mg each, followed by oral prednisone 0.5 mg/kg/day (maximum 80 mg) for four weeks, then taper to ≤10 mg/day by 4–6 months, achieving a total treatment duration of approximately six months. 13
• This three‑day pulse protocol reduces cumulative glucocorticoid exposure while preserving therapeutic efficacy compared with continuous high‑dose oral steroids. 13
• The pulse approach rapidly induces remission and lowers overall steroid burden relative to daily high‑dose oral therapy alone. 13

Subsequent Oral Steroid Management

• After the pulse course, continue oral prednisone at 0.5 mg/kg/day (not exceeding 80 mg) for at least four weeks and maintain the dose until a clinical response is evident. 13
• Taper prednisone by 5 mg every 1–2 weeks to reach ≤10 mg/day by 4–6 months; this schedule balances sustained immunosuppression with the risk of steroid‑related complications. 13

Disease‑Specific Recommendations

Lupus Nephritis (Class III/IV)

• The same pulse‑then‑prednisone regimen is specifically recommended for patients with acute severe lupus nephritis, combined with mycophenolate mofetil 3 g/day for six months as initial therapy. 13
• Patients presenting with acute renal function decline, extensive cellular crescents, or fibrinoid necrosis derive particular benefit from this combined approach. 13

Primary Nephrotic Syndrome (FSGS / Minimal Change Disease)

• Following pulse therapy, high‑dose oral prednisone should be given at 1 mg/kg/day (maximum 80 mg) or an alternate‑day regimen of 2 mg/kg (maximum 120 mg). 14
• Continue the high‑dose regimen for a minimum of four weeks and up to sixteen weeks, or until complete remission is achieved; responders typically show a reduction in proteinuria before sixteen weeks. 14

Management of Steroid‑Resistant Cases

• If no improvement is observed within the first three months after the initial pulse, a repeat three‑day course of intravenous methylprednisolone pulses may be considered. 15
• Persistent steroid resistance should prompt transition to calcineurin inhibitors (cyclosporine 3–5 mg/kg/day or tacrolimus 0.05–0.1 mg/kg/day). 14
• In lupus nephritis, steroid‑resistant patients should receive cyclophosphamide or rituximab in addition to or instead of mycophenolate. 13

Monitoring and Remission Criteria

• Assess proteinuria and serum albumin every 2–4 weeks during the initial treatment phase.
• Complete remission is defined as proteinuria <50 mg/mmol with normal or near‑normal renal function. 13
• Partial remission requires ≥50 % reduction in proteinuria to subnephrotic levels, expected by six months and no later than twelve months. 13

Critical Pitfalls and Adjunctive Measures

• Pulse methylprednisolone must not be used as monotherapy in lupus nephritis; it must be combined with mycophenolate or cyclophosphamide. 13
• High‑dose oral steroids should not be continued beyond sixteen weeks without evidence of response, to avoid unnecessary toxicity. 14
• Abrupt discontinuation of steroids after the pulse phase is contraindicated; a structured taper is essential. 13
• Prior to initiating immunosuppression for FSGS, confirm idiopathic disease and exclude secondary or genetic causes. 14
• Adjunctive therapy with ACE inhibitors or ARBs is recommended to control proteinuria, targeting systolic blood pressure <120 mmHg. 13

The overall body of evidence, including guideline statements from the rheumatology and nephrology societies, strongly supports the use of pulse methylprednisolone as a cornerstone of initial therapy for severe nephrotic syndrome, particularly in lupus nephritis. [13][15]